礼来(LLY)股价在2月6日盘中大涨5%,引起了市场广泛关注。股价上涨主要得益于公司公布了乐观的2025年业绩指引和对新一代热门产品的期待。
财报数据显示,虽然礼来2024年第四季度营收和主力产品Zepbound、Mounjaro的销售额小幅低于预期,但公司调整后每股收益5.32美元高于华尔街分析师预期。投资者关注的重点转向了公司2025年的前景。
礼来预计2025年调整后每股收益将达到22.5美元至24美元,高于分析师预期的22.86美元,预期销售额将增长32%至580亿至610亿美元。公司将在今年继续推动新产品(包括降糖药物Mounjaro和减肥新药Zepbound等)在全球其他市场的上市及销售,以实现强劲业绩增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.